DexCom signs research and development agreement with Roche

Roche Diagnostics U.S., with its business unit Roche Diabetes Care, a leader in blood glucose monitoring and insulin delivery systems, and DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring systems, announced today that they have signed a research and development agreement. The goal of this agreement is to integrate DexCom's next generation continuous glucose monitoring (CGM) system with the next generation of Accu-Chek^® insulin delivery systems targeted at the U.S. market. In the future, users of an Accu-Chek insulin pump in the U.S. will not only be able to view their blood glucose data and insulin information on their wireless handheld, but also continuous glucose monitoring readings and trends. This would enable the user to make therapy adjustments from the palm of his hand while operating the pump.

In addition, the companies signed an exclusive distribution agreement under which Roche Diabetes Care will promote DexCom's SEVEN PLUS^® CGM system for real time professional use in the U.S. The agreement allows Roche Diabetes Care to sell the DexCom SEVEN PLUS system directly to healthcare providers, who will use it with patients to promote a better understanding of individual glucose patterns and trends. This information will support healthcare providers to make better informed adjustments and to tailor therapy to the needs of a patient which can lead to an optimized diabetes management.

Luc Vierstraete, Global Head of Roche Diabetes Care, said: "Roche Diabetes Care is committed to facilitating everyday diabetes management for people with diabetes with integrated solutions that are not just intuitive to use, but also meet the requirements of individual lifestyles. With this partnership we are taking the next step in further integrating the key elements of optimal diabetes management into combined solutions that can contribute to improved medical outcomes."

"We are very pleased to partner with Roche Diabetes Care because of our companies' shared commitment to innovative, individualized therapy options," stated Terrance H. Gregg, Chief Executive Officer of DexCom. "Roche and DexCom are both focused on enabling people to better manage their diabetes by providing them with best-in-class solutions."

Roche Diabetes Care develops and commercializes solutions in the field of insulin delivery combining blood glucose monitoring, personalized insulin delivery and information management including therapy advice. One example of this new class of such integrated product solutions is the interactive Accu-Chek^® Combo system (this product is not cleared or available for use in the U.S.; a 510(k) submission is pending), allowing for enhanced convenience in managing insulin pump therapy via a smart meter remote control. DexCom's SEVEN PLUS system is the only CGM system approved for up to seven days of use enabling users to see trends and patterns in glucose readings to better control their diabetes.

Roche Diabetes Care's next generation of innovative insulin delivery systems will integrate DexCom's future CGM system - combining the proven benefits of both technologies. The proposed new solution would enable the pump system's remote control to receive the continuous glucose monitoring data directly and display this information combined with the insulin data on the color screen of the handheld. It will provide insulin pump users and their caregivers with easy access to real-time glucose values, important trending information and alerts for hypo- and hyperglycemia.

Marc Gibeley, Head of Roche Diabetes Care North America states: "Our partnership with DexCom will allow us to offer people with diabetes a single device to test their blood sugar, administer insulin and monitor short and long-term glycemic trends. This integrated solution for people with diabetes will improve their management options and allow us to strengthen our position as a leader in the U.S. market."